Patient Profile: A 49-Year-Old Woman with HR+/HER2- mBC and Liver and Lung Metastases

Finalized breast cancer screening recommendations from the United States Preventive Services Task Force suggest women aged 40 to 74 should get a mammogram every other year.

In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer.

New data from the DESTINY-Breast06 trial indicate that trastuzumab deruxtecan could become a new standard of care for patients with HER2-low and HER2-ultralow metastatic breast cancer.

In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.

During a Case-Based Roundtable® event, Hope S. Rugo, MD, FASCO, moderated a discussion on treatment options for a patient whose breast cancer recurred several years after adjuvant therapy.

The FDA has approved Lumisight and the Lumicell Direct Visualization System for fluorescence imaging in adult patients with breast cancer.